A study to campare various blood investigations in COVID-19 positive patients.
Not Applicable
Completed
- Conditions
- Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
- Registration Number
- CTRI/2020/07/026800
- Lead Sponsor
- Max Superspeciality Hospital Vaishali
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 80
Inclusion Criteria
1.Adult patients ( >18 years) admitted to the ICU who are RT-PCR confirmed covid-19 positive cases.
2.Adult patients ( >18 years) admitted to the ICU who are COVID-19 Antigen positive cases.
Exclusion Criteria
The following will be excluded from the ambit of the study:
1.Pregnant patients.
2.When prolonged antibiotic therapy is indicated (e.g., infective endocarditis, tuberculosis etc).
3.Patients with estimated length of stay less than 24 hours.
4.Severely immuno compromised patients (e.g., patients with HIV and a CD4 count <200 cells/mm3, neutropenic patients <500neutrophils/mm3 etc), patients with solid organ transplantation.
5.Patients who are bedridden with chronic multiorgan diseases.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To compare the role of INTERLEUKIN-6, PROCALCITONIN, D-DIMER, CRP and FERRITIN in terms of mortality at 28 days in confirmed covid-19 patients.Timepoint: 28 days
- Secondary Outcome Measures
Name Time Method Comparison of these inflammatory markers levels with mortality at 7 days. <br/ ><br>- Comparison of these inflammatory marker levels with duration of mechanical ventilation requirement/mechanical ventilation free days. <br/ ><br>- To study the correlation between organ failure severity and level of these inflammatory markers. <br/ ><br>- To study the correlation between levels of these inflammatory markers and total days in ICU and in hospital. <br/ ><br>Timepoint: 7 days